Novel biologic therapies under clinical evaluation for patients with high grade glioma include dendritic cell vaccination, tyrosine kinase receptor inhibitors, farnesyl transferase inhibitors, viral-based gene therapy, oncolytic viruses, vascular endothelial growth factor inhibitors and Epidermal growth factor-receptor inhibitors [25,26]. The gene discussed is EGFR; the disease is glioma.